The 100% ORR and 83.3% CR at DL2 in heavily pretreated R/R NHL patients is a strong early signal for the in vivo CAR-T platform, but the tiny sample (n=6 at DL2) and short median follow-up (2.2 months) mean durability is unproven. The EHA presentation on June 14 may provide additional detail. Monitor for longer-term follow-up data and expansion cohorts before assigning full value to the platform.
Price Chart
Executive Summary
Legend Biotech announced initial Phase 1 data for LB2501, a first-in-class in vivo CD19/CD20 dual-targeting CAR-T therapy, showing a 100% ORR and 83.3% CR at dose level 2 in relapsed/refractory B-cell NHL, with no DLTs, SAEs, or ICANS. The data will be presented at EHA 2026 on June 14, 2026. This is an early-stage, small-sample (n=12) readout that validates the in vivo CAR-T platform but requires longer follow-up and larger cohorts to confirm durability and scalability.
Key Facts
- LB2501 is a potential first-in-class in vivo CD19/CD20 dual-targeting CAR-T therapy administered as a single IV infusion without lymphodepletion
- At DL2 (n=6), ORR was 100% (6/6) and CR was 83.3% (5/6) in relapsed/refractory B-cell NHL patients with median 3 prior therapy lines
- No dose-limiting toxicities, serious adverse events, or deaths were observed; CRS was all Grade ≤2; no ICANS reported
- Dose-dependent in vivo CAR-T expansion confirmed; CAR-T cells detectable in peripheral blood for up to 116 days
- Median follow-up for DL2 was only 2.2 months (range 2.0–3.8); all responses were ongoing at data cutoff
- Data to be presented as a late-breaking oral at EHA 2026 on June 14, 2026
Financial Impact
No financial figures reported; early clinical data with no revenue or cost disclosures
Risk Factors
- Very small sample size (n=12 total, n=6 at DL2) — efficacy and safety may not replicate in larger cohorts
- Median follow-up of only 2.2 months at DL2 — response durability is unknown
- In vivo CAR-T is a novel modality with no approved precedent; regulatory and manufacturing scalability are unproven
- All responses were ongoing at cutoff, but waning or relapse could occur with longer follow-up
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003866 |
| Exhibit: exh_992.htm | 0001171843-26-003866 |
| Document: f6k_060126.htm | 0001171843-26-003866 |
| Document: 0001171843-26-003866-index-headers.html | 0001171843-26-003866 |
| Document: 0001171843-26-003866-index.html | 0001171843-26-003866 |
| Document: 0001171843-26-003866.txt | 0001171843-26-003866 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $19.80 | awaiting T+20 | — | $20.39 (+2.98%) |
Oct 13, 2026 13d ago | 6-K | $17.88 | awaiting T+20 | — | $20.39 (+14.04%) |
Sep 29, 2026 27d ago | 144 | $18.82 | awaiting T+20 | — | $20.39 (+8.34%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 15, 2026 5w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $20.39 (+15.39%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $20.39 (+10.04%) |
Aug 11, 2026 10w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $20.39 (−6.60%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $20.39 (−5.81%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $20.39 (+5.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers